drugset / Trial / NCT05563246
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
Timeline
- Start
- 2022-11-24
- Primary completion
- 2024-03-14
- Completion
- 2024-03-14
Outcome
Met primary endpoint
registry analysis (superiority test); 10 mg LY3473329 vs Placebo; p <.001; LS Mean Difference (Final Values) -47.61 (95% CI -57.68 to -35.14); Mixed Models Analysis NCT05563246 ↗
registry analysis (superiority test); 10 mg LY3473329 vs Placebo; p <.001; LS Mean Difference (Final Values) -40.38 (95% CI -50.45 to -28.27); Mixed Models Analysis NCT05563246 ↗
Publications
- Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, Haupt A, Krege JH. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2025 Jan 21;333(3):222-231. doi: 10.1001/jama.2024.24017.
- Nicholls SJ, Nelson AJ, Michael LF. Oral agents for lowering lipoprotein(a). Curr Opin Lipidol. 2024 Dec 1;35(6):275-280. doi: 10.1097/MOL.0000000000000953. Epub 2024 Sep 25.
- Karp A, Jacobs M, Barris B, Labkowsky A, Frishman WH. Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities. Cardiol Rev. 2025 Jul-Aug 01;33(4):352-358. doi: 10.1097/CRD.0000000000000667. Epub 2024 Feb 28.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Muvalaplin | Small molecule | 10 mg | Oral |
| Subject | Muvalaplin | Small molecule | 60 mg | Oral |
| Subject | Muvalaplin | Small molecule | 240 mg | Oral |
Indications
No indication recorded.